Astrazeneca AZN

AstraZeneca PLC is a global, innovation-driven biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines for the treatment of various diseases across key therapy areas. The company operates in over 100 countries and its medicines are used by millions of patients worldwide. Its core activities include research and development of new molecular entities, collaboration with partners, and the production and sale of branded pharmaceutical products. AstraZeneca has a diversified portfolio spanning Oncology, Cardiovascular, Renal and Metabolism (CVRM), Respiratory and Immunology, Vaccines and Immune Therapies, and Rare Disease treatments.

AstraZeneca generates revenue primarily through the sale of its marketed pharmaceutical products, which include both small molecule drugs and biologics. Revenue is derived from product sales in key therapeutic areas, supported by collaboration and alliance revenues from partnered products. The company sells its medicines to wholesalers, distributors, hospitals, pharmacies, and healthcare providers, with revenue recognized upon transfer of control to the customer. In 2025, total product sales reached $55,573 million, driven by strong performance across all therapy areas, particularly in the United States, Emerging Markets, and Europe.

The company operates through the following segments: Oncology, BioPharmaceuticals (which includes CVRM, Respiratory & Immunology, and Vaccines & Immune Therapies), and Rare Disease.

• Oncology: This segment focuses on the development and commercialization of medicines for the treatment of various cancers, including lung, breast, ovarian, prostate, and hematologic malignancies. Key products include Tagrisso (osimertinib) for EGFR-mutated non-small cell lung cancer, Imfinzi (durvalumab) for unresectable stage III NSCLC and hepatocellular carcinoma, Lynparza (olaparib) for BRCA-mutated cancers, Calquence (acalabrutinib) for chronic lymphocytic leukemia and mantle cell lymphoma, and Enhertu (trastuzumab deruxtecan) for HER2-positive breast and gastric cancers. The segment also includes Truqap (capivasertib) for HR-positive, HER2-negative advanced breast cancer and Datroway (datopotamab deruxtecan) for metastatic breast cancer and EGFR-mutated NSCLC.
• CVRM: This segment addresses cardiovascular, renal, and metabolic diseases, including heart failure, chronic kidney disease, hypertension, and dyslipidaemia. Major products include Farxiga/Forxiga (dapagliflozin) for type 2 diabetes, heart failure, and chronic kidney disease; Brilinta/Brilique (ticagrelor) for acute coronary syndromes; Lokelma (sodium zirconium cyclosilicate) for hyperkalaemia; Roxadustat for anaemia in chronic kidney disease; and Wainua (eplontersen) for hereditary transthyretin-mediated amyloidosis. The segment also includes combination therapies such as Zigduo/Xigduo XR (dapagliflozin/metformin) and emerging agents like laroprovstat and baxdrostat.
• Respiratory & Immunology: This segment focuses on respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), as well as immunological disorders including systemic lupus erythematosus and eosinophilic diseases. Key products include Symbicort (budesonide/formoterol) for asthma and COPD; Breztri/Trixeo (budesonide/glycopyrrolate/formoterol) for COPD; Fasenra (benralizumab) for severe eosinophilic asthma; Tezspire (tezepelumab) for severe asthma and chronic rhinosinusitis with nasal polyps; Saphnelo (anifrolumab) for systemic lupus erythematosus; and Airsupra (albuterol/budesonide) as a rescue medication for asthma. The segment also includes vaccine candidates and immune therapies targeting infectious diseases.
• Vaccines & Immune Therapies: This segment includes products aimed at preventing infectious diseases through immunization and immune modulation. Key offerings are Beyfortus (nirsevimab) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants, FluMist (live attenuated influenza vaccine) for seasonal influenza prevention, and Synagis (palivizumab) for high-risk infants to prevent severe respiratory syncytial virus infection. The segment also includes investigational vaccines and monoclonal antibodies targeting pathogens such as Staphylococcus aureus and Clostridioides difficile.
• Rare Disease: This segment focuses on treating rare, often genetic, disorders with significant unmet medical needs. Key products include Ultomiris (ravulizumab) for paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, generalised myasthenia gravis, and neuromyelitis optica spectrum disorder; Soliris (eculizumab) for similar indications; Strensiq (asfotase alfa) for hypophosphatasia; Koselugo (selumetinib) for neurofibromatosis type 1; and investigational therapies such as ALXN2080 for complement-mediated diseases and efimotase alfa for hypophosphatasia. The segment also includes gene therapies like ALXN2350 DCMRestore for BAG3-associated dilated cardiomyopathy.

AstraZeneca holds a strong position in the global pharmaceutical industry, competing with major players such as Pfizer, Merck, Roche, Novartis, and Johnson & Johnson. The company differentiates itself through a focused strategy on Oncology, Rare Disease, and BioPharmaceuticals, supported by a robust pipeline of new molecular entities and strategic collaborations. Its competitive advantages include deep scientific expertise, a global commercial footprint, and a track record of successful product launches and lifecycle management. AstraZeneca consistently ranks among the top pharmaceutical companies by research and development investment and market capitalization.

The company serves a diverse customer base comprising patients, healthcare providers, hospitals, clinics, pharmacies, wholesalers, and distributors across the globe. Its medicines are used in inpatient and outpatient settings for the treatment of chronic and acute conditions. AstraZeneca collaborates with government health systems, managed care organizations, and group purchasing organizations, particularly in the United States and Europe, to ensure broad access to its therapies. Specific customer relationships include partnerships with Sanofi for Beyfortus distribution and Amgen for Tezspire co-development and commercialization.